Inhibition of Plasma Kallikrein with Aprotinin in porcine endotoxin Shock by Siebeck, Matthias et al.
0022-5282/93/3402-0193$03.00/0 
T H E JOURNAL OF TRAUMA 
Copyright © 1993 by Williams & Wilkins 
Vol. 34, No. 2 
P r i n t e d i n U . S . A . 
INHIBITION OF PLASMA KALLIKREIN WITH APROTININ IN 
PORCINE ENDOTOXIN SHOCK 
Matthias Siebeck, MD,a Edwin Fink, PhD,b Joachim Weipert, MD,b Marianne Jochum, PhD,b Hans Fritz, PhD,b 
Michael Spannagl, MD,C Peter Kroworsch," Kazuaki Shimamoto, MD,d and Leonhard Schweiberer,11 MD 
Activation of the contact phase of coagulation has been implicated in the 
pathogenesis of septic shock. W e wanted to determine if inhibition of plasma 
kallikrein can prevent arterial hypotension and liberation of kinins from kininogen, 
induced by an infusion of bacterial l ipopolysaccharide (LPS) in anesthetized, 
ventilated 20-kg pigs. The L P S was given IV in a dose of 5 /xg /kg/h for 8 hours. The 
plasma kallikrein inhibitor aprotinin, 537 pmo\, was given IV during 8 hours, resulting 
in plasma levels above 10 ^mol /L . Ten animals (SA) received L P S and aprotinin and 
ten randomized controls (SC) received L P S and saline. Kinin-containing kininogen 
was determined on the basis of the amount of kinin releasable in plasma samples by 
incubation with trypsin. Kininogen decreased to 58% ± 4% of the baseline value 
without any difference between groups. This may indicate participation of other 
p rocesses than degradation by plasma kallikrein in the decrease of kininogen. 
Arterial blood pressure was higher at 7 hours in the S A animals than in the S C group 
(101% ± 11% vs . 68% ± 8%; mean ± S E M ; p = 0.026). Fibrin monomer and C3a<*, A r g 
plasma levels were attenuated by aprotinin treatment. T h e s e findings underscore the 
important role of the contact system in L P S shock. 
B A C T E R I A L L I P O P O L Y S A C C H A R I D E (LPS) is re-
garded as one of the causative agents of gram-negative 
sepsis and has been demonstrated to activate the contact 
phase of the intrinsic blood coagulation cascade in vi-
tro. 1 , 2 Arterial hypotension is induced by LPS in many 
species of experimental animals. Both the contact and 
the complement systems have been found to be activated 
in patients with septic shock.3 
Activation of the contact system of blood coagulation 
(Fig. 1) occurs as reciprocal activation of plasma kalli-
krein and Hageman factor (factor XII) in the presence 
of a negatively charged surface and high molecular weight 
kininogen (HMr kininogen) as cofactors.4 Activation 
leads to release of bradykinin from kininogen by plasma 
kallikrein, 5 intrinsic blood coagulation, fibrinolysis,6 
complement activation,7 and neutrophil stimulation.8 
The potent hypotensive oligopeptide bradykinin has 
been implicated in the pathophysiology of shock.9 De-
creased kininogen and prekallikrein concentrations10 and 
elevated kinin levels11 in plasma have been repeatedly 
described in experimental L P S shock and in patients 
with septic shock. Using a specific kinin receptor antag-
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onist it was demonstrated that kinins mediate L P S -
induced arterial hypotension in rats.12 
According to these results generation of active plasma 
kallikrein by contact system activation and subsequent 
release of bradykinin could play an important role in the 
pathophysiology of LPS-induced shock. To test this hy-
pothesis we investigated whether in vivo inhibition of 
plasma kallikrein with aprotinin, a plasma kallikrein 
inhibitor,1 3 would block or attenuate the effect of L P S 
on blood pressure and the concentration of uncleaved 
kininogen in pigs. Further questions concerned the effect 
of aprotinin on LPS-induced respiratory failure and on 
activation of the complement and coagulation systems. 
MATERIALS AND METHODS 
Miniature pigs (Medical Service GmbH, Munich) with a 
body weight ranging from 18.0 to 22.0 kg were used in our 
study. All animal procedures were approved by the government 
of Oberbayern. The animals were fasted overnight but had free 
access to water. Sedation was achieved by intramuscular injec-
tion of azaperone, 3 mg/kg, and metomidate, 3.75 mg/kg. After 
induction of anesthesia with intravenous pentobarbital sodium, 
24 mg/kg, volume-cycled mechanical ventilation was instituted 
with a Servo Ventilator 900C (Siemens Elema AB, Sweden) at 
constant settings. Tidal volume was increased only if carbon 
dioxide partial pressure in arterial blood rose above 40 mm Hg 
during the experiment. Metabolic acidosis was corrected with 
infusion of 1 N NaHC0 3 solution if base excess reached -2 
mEq/L in hourly arterial blood gas analyses. A 7F thermistor-
tipped Swan-Ganz catheter was placed in the internal jugular 
vein and passed to the pulmonary artery; three venous catheters 
for infusions and a short large-bore cannula for sampling blood 
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Figure 1. The contact system of blood coagulation. When the zym-
ogens, Hageman factor (factor XII), and prekallikrein are bound to HMr 
kininogen and brought into contact with a negatively charged surface, 
they activate each other mutually. The active factor XII (factor Xlla) 
converts more prekallikrein into active plasma kallikrein, which in turn 
converts more factor XII into factor Xlla and cleaves the peptide brady-
kinin from HMr kininogen. Plasma kallikrein and factor Xlla initiate several 
other metabolic pathways such as the coagulation, complement, and 
fibrinolysis cascades. Plasma kallikrein stimulates granulocytes; brady-
kinin stimulates endothelial cells and induces hypotension. All of these 
events could be possibly blocked by an inhibitor of plasma kallikrein. 
were placed in the external jugular vein. Piritramide, 15 mg, 
and pancuronium bromide, 4 mg, were given intravenously. 
Piritramide was continued at a rate of 0.5 mg/kg/h and pan-
curonium bromide at a rate of 0.3 mg/kg/h. Additional pento-
barbital sodium, 4 mg/kg, was injected when necessary. Blood 
pressure was measured with a strain gauge connected to an 
aortic catheter placed via a femoral incision. A cystostomy tube 
was placed from a small midline incision, and urine was col-
lected in hourly samples. During a 60-minute resting period 
after the end of the surgical procedure 500 mL of Ringer's 
solution was infused. 
Lipopolysaccharide shock was induced by a continuous in-
fusion of bacterial lipopolysaccharide from Salmonella abortus 
e q u i 1 4 (Sebak GmbH, Aidenbach, Germany). The LPS was 
dissolved in saline and given in a dose of 5 ng/kg/h for 8 hours. 
Aprotinin (M r 6512) was supplied by Bayer AG, Wuppertal 
(Batch No. 8078) as a white lyophilized powder with a specific 
activity of 7151 KIU/mg polypeptide. Aprotinin, 3.5 g (425 
million KIU â 537 /umol), was freshly dissolved in saline and 
administered intravenously as a bolus of 750 mg for 3 minutes 
before the start of LPS infusion followed by a continuous 
infusion of 2750 mg for 8 hours. This dosage had been deter-
mined in eight pilot experiments. 
After certain predetermined entry criteria had been fulfilled, 
baseline measurements were taken and the animals were ran-
domly assigned to the study groups. Ten animals received LPS 
and aprotinin (SA) and ten controls received LPS and saline 
(SC). Animals were sacrificed after 8 hours of observation. Four 
nonseptic controls received saline and aprotinin in the afore-
mentioned dose (NA); these animals were observed for 6 hours 
only. Five nonseptic controls received saline only (NN). Only 
the prekallikrein measurements were reported of this latter 
group. Blood samples were drawn at baseline and hourly there-
after, and processed to EDTA, or heparinized or citrated 
plasma, respectively, and kept at -80 °C until assayed. 
Total kinin-containing kininogen was determined as follows: 
20 nL of heparinized plasma was mixed with 180 0.03 mol/ 
L HCl and incubated for 15 minutes at 37°C. Thereafter, 10 fiL 
0.5 mol/L NaCl, 30 M L 0.3 mol/L TRIS/HC1, pH 7.8, and 10 
ML of a trypsin solution (bovine trypsin, 2 mg/mL in 2.5 mmol/ 
L HCl) were added). After an incubation for 30 minutes at 37°C 
the solution was mixed with 1 mL 98% ethanol and heated for 
10 minutes at 70°C. After centrifugation at 12,000g the super-
natant was quantitatively transferred to a new tube and the 
ethanol was removed under vacuum in a SpeedVac concentra-
tor. The dry residue was dissolved in radioimmunoassay buffer 
and the kinin concentration was determined by radioimmuno-
assay as described previously.15 
Aprotinin concentration in citrated plasma samples was 
determined using an enzyme immunoassay.16 Plasma kallikrein 
was measured as the amount of latent prekallikrein in the 
sample that can be converted to the active enzyme by the 
addition of a mixture of ellagic acid, phospholipid, factor XII, 
and HMr kininogen (Kabi Vitrum, Mölndal, Sweden). The 
active plasma kallikrein was determined in a photometric assay 
using the chromogenic substrate S2302. The reaction is inhib-
ited by aprotinin, therefore prekallikrein could not be deter-
mined in animals receiving aprotinin. 
Plasma levels of C3a<iesArg were determined with a newly 
developed radioimmunoassay similar to that described for hu-
man C S a d e s A r g 1 7 The C3ad e 9Arg was isolated from porcine blood18 
and antiserum to C3a<iesArg was developed in rabbits. 
Buffers 
Buffer A: 0.015 mol/L NaH 2P0 4 , 0.15 mol/L NaCl, pH 7.4; ' 
buffer B: 0.015 mol/L NaH 2P0 4 , 0.15 mol/L NaCl, 200 
mg/L thimerosal, 1.0 g/L NaN 3, 42 g/L bovine serum albumin, 
pH 7.4; buffer C: 0.05 mol/L NaH 2P0 4 , 0.1 mol/L NaCl, 200 
mg/L thimerosal, 0.5 g/L NaN 3, 400 / tL /L Tween 20, pH 7.4; 
buffer D: 8.0 g/L ethodin in 0.05 mol/L NaH 2P0 4, pH 7.4, 
freshly prepared immediately before use; buffer E: 0.015 mol/ 
L NaH 2P0 4, 0.15 mol/L NaCl, 200 mg/L thimerosal, 60 g/L 
polyethylene glycol 6000. 
Radioiodination 
The C3a<ie8Arg was labeled with iodine-125 by the chloramine 
T method.19 Then 2.5 Mg C S a ^ , 0.33 mCi (12.3 MBq) Na1 2 5I, 
and 30 fig chloramine T were incubated for 5-10 seconds in 
buffer A (total volume 25 /uL), and 60 fig sodium disulfite 
dissolved in 60 yiL buffer A was added. The iodinated C3a<ie8Arg 
was purified by gel filtration of the mixture through a PD-10 
column (Pharmacia). The column was eluted with buffer A. 
The pool of labeled C3ad e 8Arg was diluted with buffer C to 
500,000 counts • min - 1 mL - 1 , and 140 mg/L of rabbit immuno-
globulin G was added. 
Sample Preparation 
Protein precipitation with 6,9-diamino-2 ethoxyacridine lac-
tate (ethodin, Sigma Chemie, Deisenhofen)20 was employed to 
remove C3. One hundred microliters of EDTA-plasma was 
mixed with 100 u h buffer D in Eppendorf tubes. After 20 
minutes at room temperature the samples were centrifuged for 
10 minutes at 10,000g. Dilutions of the supernatant with buffer 
C were analyzed in the radioimmunoassay. 
Radioimmunoassay Procedure 
The incubation mixtures consisting of 50 fih of standard 
(1.0-500 Mg/L) or sample in buffer C, 50 p L iodinated C3a<iesArg 
in buffer C, 50 fiL buffer C, and 50 fih dilution of antiserum in 
buffer B were set up in 0.6-mL RIA tubes (Sarstedt, Nürm-
brecht). After 12-18 hours' incubation at room temperature, 50 
/iL of a dilution of the precipitating antiserum (donkey anti-
serum to rabbit IgG, IDS, Washington, United Kingdom) in 
buffer B and 250 /uL buffer E was added. The tubes were 
centrifuged immediately for 20 minutes at 3500g. The radioac-
tivity of the precipitates was measured in a gamma counter 
(Hydragamma 16; Zinsser, Frankfurt), and the results were 
evaluated on line by the RIALOG II program (Zinsser, Frank-
furt). 
Fibrin monomer was detected in plasma by a monoclonal 
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antibody-based specific enzyme immunoassay; the capturing 
antibody used detects the N-terminal a-chain of porcine fibrin. 
The second antibody detected porcine fibrinogen. Thrombin 
digestion of known amounts of fibrinogen in pig plasma was 
used for standard preparation. The clottable fibrinogen in 
citrated plasma samples was measured using a functional tur-
bidimetric test with batroxobin (Boehringer Mannheim, Ger-
many). Total protein in plasma was measured with the Biuret 
reaction. 
White blood cell counts were performed on a Contraves 
Hemocytometer. Alveolar-arterial oxygen gradient ( P A 0 2 - P a 0 2 ) 
was calculated from arterial blood gas analyses made on a 
Corning Model 168 Blood Gas Analyzer and a Radiometer 
OSM2 Hemoximeter. Dynamic total compliance was calculated 
from data generated by the ventilator. Cardiac output was 
determined by the thermodilution method, and pulmonary vas-
cular resistance (PVR) and systemic vascular resistance (SVR) 
were calculated. Creatinine was determined in plasma and urine 
using the picric acid method, and plasma clearance was calcu-
lated at 60-minute intervals. 
After checking data for normality of distribution the two-
tailed Student's t test was performed to compare the results of 
the two septic groups. Data were expressed as a percentage of 
the baseline value unless indicated as raw data. Mean values, 
standard error of the mean (SEM), and exact p values were 
reported; no correction for multiple testing was made; p values 
less than 0.05 were considered significant. The Wilcoxon 
signed-rank test was used for paired data. Survival was deter-
mined from the start of the LPS infusion to death; data were 
compared with the Mantel-Haenszel test. 
RESULTS 
Circulation 
Mean arterial blood pressure (MAP) followed a bi-
phasic time course during LPS infusion, was not different 
between groups at baseline, but was higher at 7 hours in 
the SA group than in the SC group (101% ± 11% vs. 
68% ± 8%; p = 0.026; Fig. 2). Systemic vascular resist-
ance (SVR) followed a time course similar to that of 
M A P , was marginally different between groups at base-
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Figure 2. Mean arterial blood pressure (MAP) during LPS shock. 
Means ± SEM (vertical bars) in percentage of the baseline value are 
given. Ten septic control animals (SC) received LPS, 5 M9/kg/h for 8 
hours and 0.9% NaCl for 8 hours. Ten septic aprotinin-treated animals 
(SA) received LPS in the aforementioned dose, and aprotinin, 3.5 g, for 
8 hours. Pressure was higher in the SA group than in the SC group at 7 
hours (p = 0.026). 
0 2 4 6 8 
T ime ( h ) 
Figure 3. Systemic vascular resistance (SVR), pulmonary vascular 
resistance (PVR), cardiac output (CO), and alveolar-arterial oxygen gra-
dient (A-aD02) during LPS shock. (A) The SVR was not significantly 
higher in the SA group than in the SC group. (B) The PVR was lower in 
the SA group than in the SC group at 2 hours (p = 0.04). (C) The CO 
was identical in the two groups. (D) The Alveolar-arterial oxygen gradient 
was identical in the two groups. 
line (p = 0.06), and was not significantly higher in the 
SA group than in the SC group during LPS infusion (Fig. 
3A). Cardiac output (CO) was not different between 
groups either at baseline or during the L P S infusion (Fig. 
3C). 
Lung 
Compliance dropped to 55% of the baseline; the alveo-
lar-arterial oxygen gradient rose to 191% of the baseline 
value (Fig. 3D). No significant group differences devel-
oped for either of these variables during L P S infusion. 
Pulmonary vascular resistance followed a multiphasic 
time course with a peak at 30 minutes, a decline, and a 
secondary rise from 2 hours to 6 hours. At 2 hours, P V R 
was lower in the SA group (207% ±23%) compared with 
the SC group (287% ± 21%; p = 0.04; Fig. 3B). The 
results were similar for P A P (p = 0.004). Survival was 
65% during 8 hours of L P S infusion; the groups were not 
significantly different (70% in the SC group, 60% in the 
SA group). 
Blood 
Kininogen concentration was not different between 
groups either at baseline or during LPS infusion and 
decreased to 58 ± 4% of the baseline value (Fig. 4). Total 
protein concentration in plasma was not different be-
tween groups either at baseline or during L P S infusion 
and decreased to 69% ± 2% of the baseline value (Fig. 
5A). At 8 hours, the relative deviation from the baseline 
value was larger for kininogen than for total protein ( p 
= 0.01). Fibrin monomer was near the detection limit of 
the assay at baseline. During LPS infusion, fibrin mon-
omer was considerably lower in the SA animals (59% ± 
12 Mg/mL) than in the SC pigs (152% ± 27 Mg /mL; p = 
0.013 at 8 hours; Fig. 5B). Fibrinogen decreased to 35% 
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Figure 4. Total kininogen during LPS shock. Ten septic control 
animals (SC) received LPS, 5 Mg/kg/h for 8 hours and 0.9% NaCl for 8 
hours. Ten septic aprotinin-treated animals (SA) received LPS in the 
aforementioned dose, and aprotinin, 3.5 g for 8 hours. Groups were not 
significantly different. The assay detects only kinin-containing kininogen 
but not des-bradykinin-HMr kininogen. 
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Figure 5. Total protein, fibrin monomer, C3adesArg in plasma, and 
creatinine clearance during LPS shock. Ten septic control animals (SC) 
received LPS, 5 ^g/kg/h for 8 hours and 0.9% NaCl for 8 hours. Ten 
septic aprotinin-treated animals (SA) received LPS in the aforementioned 
dose, and aprotinin, 3.5 g for 8 hours. (A) Total protein was identical in 
the two groups. (B) Fibrin monomer concentration was substantially 
lower at 8 hours in the SA group than in the SC group (p = 0.013). (C) 
Complement fragment C3adesArg was slightly lower in the SA pigs than in 
the SC animals during the first 5 hours. (D) Creatinine clearance was 
nonsignificantly lower in the SA group than in the SC group. 
at 8 hours. Fibrinogen was slightly higher at 6 hours in 
the SA group than in the SC group (52% ± 8% vs. 35% 
± 5%; NS). The C3a<iesArg level rose during L P S infusion 
to 195% ± 14% of the baseline value at 8 hours. During 
the first 5 hours C3adeSArg was slightly (NS) lower in the 
SA pigs than in the SC group (Fig. 5C). White blood cell 
count dropped to 20%, without differences between the 
septic groups. Diuresis and creatinine clearance (Fig. 5D) 
were nonsignificantly lower in the SA group than in the 
SC group at 8 hours. Aprotinin concentration rose from 
468 ± 56 K I U / m L at 1 hour to 623 ± 222 K I U / m L at 8 
hours (10 ± 1.2 to 13.6 ± 4.8 /nmol/L) in the SA animals 
and from 423 ± 61 K I U / m L at 1 hour to a maximum of 
525 ± 85 at 5 hours in the N A group. Prekallikrein 
concentration decreased within 8 hours to 53% ± 5% of 
the baseline value in the SC group and to 94% ± 5% in 
nonseptic controls (NN; Fig. 6). 
In the nonseptic aprotinin-treated animals (NA), total 
protein was completely stable. Minor deviations from 
normal were found for P A O 2 - Pa0 2, PVR, CO, SVR, 
blood pressure, fibrinogen, and creatinine clearance. 
Plasma levels of C3adeSArg, prekallikrein, and kininogen 
were not determined in this group. 
DISCUSSION 
According to our primary hypothesis, activation of the 
contact system is important in the pathophysiology of 
LPS-induced shock and this activation induces the re-
lease of bradykinin from kininogen by activated plasma 
kallikrein. If this is the case, the administration of a 
plasma kallikrein inhibitor should reverse arterial hy-
potension and reduce LPS-induced kininogen break-
down. In fact, we found a significant reduction of LPS-
induced hypotension. Since cardiac output had an iden-
tical time course whether or not aprotinin was given this 
difference in arterial blood pressure can be entirely at-
tributed to a similar difference in the systemic vascular 
resistance. 
To model the clinical situation of patients with gram-
negative sepsis, we gave a continuous infusion of LPS in 
a dose of 5 Aig/kg/h for 8 hours. Most shock studies in 
rodents use 100 to 1000-fold higher LPS doses. Injection 
of LPS from E . coli has been investigated in humans. 
However, septic shock and death are not acceptable risks 
for volunteers, and therefore much smaller doses (4 ng/ 
kg) have been used.21 Patients with gram-negative sepsis 
had endotoxin levels of between 6 and more than 100 
o 
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Figure 6. Prekallikrein in plasma with and without LPS shock. Ten 
septic control animals (SC) received LPS, 5 Mg/kg/h for 8 hours. Five 
nonseptic control animals (NN) received 0.9% NaCl only. Prekallikrein 
levels decreased in the SC group but not in the NN group. Prekallikrein 
could not be measured in aprotinin-treated animals because a functional 
assay was used that is based on activation of prekallikrein to active 
plasma kallikrein, and measurement of the activity of plasma kallikrein 
thus released. Aprotinin, being a plasma kallikrein inhibitor, inhibits this 
reaction. 
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ng/L in blood.2 2 Pigs with endotoxin infusion in experi-
ments similar to ours had endotoxin levels of approxi-
mately 4 ng/mL. 2 3 We did not select mortality as a 
primary study criterion because a longer observation 
period and a higher case number would have been nec-
essary to detect an effect of aprotinin on survival. Small 
animals are better suited for this type of study, and other 
study conditions, e.g., a smaller dose of lipopolysaccha-
ride, might have shown some improvement in mortality. 
To assess cleavage of kininogen we used a method that 
determined the plasma concentration of kininogen by 
measuring the amount of kinin that can be released from 
a plasma sample by digestion with trypsin. In contrast 
to methods that employ antibodies directed against 
either high molecular weight kininogen (HMrK) or low 
molecular weight kininogen (LMrK) , this method rec-
ognizes both H M r K and L M r K but only those kininogen 
molecules that still contain the kinin sequence. Using 
this method we found no difference of kininogen levels 
between the two septic groups. This finding suggests that 
activation of plasma kallikrein was not the only event 
responsible for the observed decrease in kininogen, which 
exceeded the decrease in total protein concentration 
significantly but only by 11%. Processes other than 
proteolysis, e.g., the LPS-induced vascular leak syn-
drome or blood sampling, contribute to the decrease of 
plasma protein concentration in our experiments, and 
proteases other than plasma kallikrein may have con-
tributed to the degradation of kininogen,24 e.g., polymor-
phonuclear elastase.25 
It may be argued that our model of L P S shock failed 
to induce contact phase activation. Because of the prin-
ciple of the plasma kallikrein assay used (determination 
of the kallikrein activity after in vitro activation of 
prekallikrein in the sample), it is not possible to deter-
mine kallikrein activity in the presence of high amounts 
of aprotinin. However, plasma kallikrein was activated 
in the LPS-treated animals as assessed in the absence of 
aprotinin by a substantial decrease in prekallikrein lev-
els. Similarly, we have found in a previous study a 
decrease in the plasma activity of inhibitors of plasma 
kallikrein, C l esterase inhibitor, and a2-macroglobulin.26 
Aprotinin is a relatively weak plasma kallikrein inhib-
itor. However, the aprotinin plasma levels in our exper-
iments exceeded 468 K I U / m L (10 ^mol/L) and should 
therefore have blocked relevant amounts of plasma kal-
likrein in the circulation. 2 ' 2 8 This notion is supported by 
a previous study in which high amounts of plasma kal-
likrein, rapidly generated in an in vivo model of dextran 
sulfate-induced activation of the contact phase of coag-
ulation, were completely blocked at an aprotinin concen-
tration of 400 K I U / m L . 2 9 
Since the extent of kininogen cleavage was not influ-
enced by administration of aprotinin, the question arises 
why aprotinin then attenuated arterial hypotension. 
Aprotinin has been found to prevent the release of ara-
chidonic acid from the membrane phospholipid pool 3 0 
and may thus inhibit the formation of prostanoids. 
Therefore it may even have an effect on blood pressure 
not related to kinins. 
Contact system activation leads to activation of the 
coagulation, fibrinolysis, and complement pathways. 
C3a<iesArg, a stable and biologically inert split product of 
C3a, showed a trend toward lower levels in aprotinin-
treated animals compared with controls during the first 
5 hours of the LPS infusion, possibly indicating reduced 
complement activation. The formation of fibrin mon-
omer was substantially reduced by aprotinin, and fibrin-
ogen concentrations were higher during the last 3 hours 
in the SA animals than in the SC pigs, each finding 
indicating reduced activation of coagulation. Both the 
complement and the coagulation effects may have been 
produced by contact system inhibition, which would 
underline that plasma kallikrein activation had taken 
place in our experiment and was subject to inhibition by 
aprotinin. 
It is important to note that aprotinin had no effect on 
leukocytopenia and respiratory dysfunction, both of 
which are very constant features of porcine LPS shock. 
An adverse side effect of high levels of aprotinin in septic 
shock may be impairment of renal function. Aprotinin 
given alone had no detrimental side effects, not even on 
renal function. 
In summary, LPS-induced arterial hypotension, fibrin 
monomer formation, and C3adeSArg release were atten-
uated by aprotinin at plasma levels around 10 ^mol/L, 
indicating the involvement of the contact system in the 
pathophysiology of LPS shock. Aprotinin had no effect 
on the kininogen decrease. We suggest that, in addition 
to plasma kallikrein, other processes contributed to kin-
inogen turnover. 
Acknowledgments 
The study was carried out with the technical assistance of 
A. Braune, J. Kohl, C. Keser, G. Godec, and A. Oettl. This 
study was supported by a grant from the Bundesministerium 
des Inneren. Aprotinin was a generous gift of Dr. F. Schumann, 
Bayer AG, Wuppertal. C3ad e S Ar g isolated from porcine blood and 
antiserum to C3ad e S Ar g developed in rabbits was kindly provided 
by the late Prof. Damerau, Max-Planck-Institut für experimen-
telle Medizin, Göttingen. Dr. J. Weipert was the recipient of a 
fellowship from the Deutsche Forschungsgemeinschaft. 
REFERENCES 
1. Morrison DC, Cochrane CG: Direct evidence for Hageman factor 
(factor XII) activation by bacterial lipopolysaccharides (endo-
toxins). J Exp M e d 140:797, 1974 
2. Kalter ES, van Dijk WC, Timmerman A, et al: Activation of 
purified human plasma prekallikrein triggered by cell wall frac-
tions of Escherichia coli and Staphylococcus aureus. J Infect Dis 
148:682, 1983 
3. Kalter ES, Daha MR, ten Cate JW, et al: Activation and inhibition 
of Hageman factor-dependent pathways and the complement 
system in uncomplicated bacteremia or bacterial shock. J Infect 
Dis 151:1019, 1985 
4. Cochrane CG, Griffin JH: The biochemistry and pathophysiology 
of the contact system of plasma. Adv I m m u n o l 33:241, 1982 
198 The Journal of Trauma F e b r u a r y 1993 
5. Kaplan AP: Hageman factor-dependent pathways: Mechanism of 
initiation and bradykinin formation. Fed Proc 42:3123, 1983 
6. Colman RW: Activation of plasminogen by human plasma kalli-
krein. Biochem Biophys Res Commun 35:273, 1969 
7. Ghebrehiwet B, Randazzo BP, Dunn JT, et al: Mechanisms of 
activation of the classical pathway of complement by Hageman 
factor fragment. J Clin Invest 71:1450, 1983 
8. Wachtfogel YT, Kucich U, James HL, et al: Human plasma kalli-
krein releases neutrophil elastase during blood coagulation. J 
Clin Invest 72:1672, 1983 
9. Rocha é Silva M, Beraldo WT, Rosenfeld G: Bradykinin, a hypo-
tensive and smooth muscle stimulating factor released from 
plasma globulin by snake venoms and by trypsin. A m J Physiol 
156:261, 1949 
10. Aasen AO, Smith Erichsen N, Gallimore MJ, et al: Studies on 
components of the plasma kallikrein-kinin system in plasma 
samples from normal individuals and patients with septic shock. 
Adv Shock Res 4:1, 1980 
11. O'Donnell TF, Clowes GHA, Talamo RC, et al: Kinin activation 
in the blood of patients with sepsis. Surg Gynecol Obstet 143:539, 
1975 
12. Weipert J, Hoffmann H, Siebeck M, et al: Attenuation of arterial 
blood pressure fall in endotoxin shock in the rat using the 
competitive bradykinin antagonist Lys-Lys-[Hyp2,Thi5,8, DPhe7] 
-BK (B4148). B r J P h a r m a c o l 94:282,1988 
13. Fritz H, Wunderer G: Biochemistry and applications of aprotinin, 
the kallikrein inhibitor from bovine organs. D r u g Res 33:479, 
1983 
14. Galanos C, Lüderitz O, Westphal O: Preparation and properties of 
a standardized lipopolysaccharide from S a l m o n e l l a abortus equi 
Z e n t r a l b l B a k t e r i o l Orig A 243:226, 1979 
15. Fink E, Schill WB, Fiedler F, et al: Tissue kallikrein of human 
seminal plasma is secreted by the prostate gland. B i o l Chem 
Hoppe Seyler 366:917, 1985 
16. Müller-Esterl W: Enzyme-linked immunosorbent assay for aproti-
nin. In Bergmeyer IU (ed): Methods of Enzymatic Analysis, Vol. 
XII. Weinheim, VCH Verlagsgesellschaft, 1986, pp 246-256 
17. Hugh TE, Chenoweth D: Biologically active peptides of comple-
ment: Techniques and significance of C3a and C5a measure-
ments. In Nakamura R, Dito S, Tucker E (eds): Immunoassays: 
Clinical Laboratory Techniques for the 1980s. New York, Alan R. 
Liss Inc., 1980, pp 443-460 
18. Zimmermann B, Damerau B, Vogt W: Purification and partial 
amino acid sequence of classical anaphylatoxin from pig serum: 
Identification with Des-Arg-C5a. Hoppe-Seylers Z Physiol Chem 
361:915, 1980 
19. Greenwood FC, Hunter WL, Glover JJ: The preparation of 131I-
labelled growth hormone of high specific activity. Biochem J 
89:114, 1963 
20. Steinbuch M, Niewiarowski S: Rivanol in the preparation of plas-
minogen (Profibrinolysin). N a t u r e 186:87, 1960 
21. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular 
response of normal humans to the administration of endotoxin. 
N Engl J M e d 321:280,1989 
22. van Deventer SJ, Buller HR, ten Cate JW, et al: Endotoxaemia: 
An early predictor of septicaemia in febrile patients. Lancet 
1(8586):605, 1988 
23. Borg T, Alvfors A, Gerdin B, et al: A porcine model of early adult 
respiratory distress syndrome induced by endotoxinaemia. Acta 
Anaesthesiol Scand 29:814, 1985 
24. McConn R, Wassermann F, Haberland G: The kallikrein-kinin 
system in the acutely ill: (A) Changes in plasma kininogen in 
acutely-ill patients. (B) The efficacy of pulmonary clearance of 
bradykinin. Adv Exp M e d B i o l 156:1019, 1983 
25. McGuire WW, Spragg RG, Cohen AB, et al: Studies on the path-
ogenesis of the adult respiratory distress syndrome. J Clin Invest 
69:543, 1982 
26. Siebeck M, Philapitsch A, Wiesinger H, et al: Cl-Esterase inhibitor 
in early septicemia. Prog Clin Biol Res 236A:141, 1987 
27. Philipp E: Calculations and hypothetical considerations on the 
inhibition of plasmin and plasma kallikrein by trasylol. In Dav-
idson JF, Rowan RM, Samama MM, Desnoyers PC (eds): Prog-
ress i n Chemical Fibrinolysis and Thrombolysis, Vol 3. New York, 
Raven Press, 1978, pp 291-295 
28. Fritz H: Inhibition of plasmin and plasma kallikrein by the basic 
trypsin-kallikrein inhibitor from bovine organs (Trasylol) and 
similar protease inhibitors: Theoretical considerations. In Dav-
idson JF, Rowan RM, Samama MM, Desnoyers PC (eds): Prog-
ress i n Chemical Fibrinolysis and Thrombolysis, Volume 3. New 
York, Raven Press, 1978, pp 285-290 
29. Hoffmann H, Siebeck M, Thetter O, et al: Aprotinin concentrations 
effective for the inhibition of tissue kallikrein and plasma kalli-
krein i n vitro and i n vivo. Adv Exp M e d B i o l 247B:35, 1989 
30. Seeger W, Wolf H, Graubert E, et al: Influence of aprotinin and 
gabexate mesilate on arachidonic acid release by the Ca-iono-
phore A 23187 in the lung. Adv Exp M e d B i o l 156:553, 1983 
